Robert E. Schmidt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robert E. Schmidt has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Karen G. Green
4 shared publicationsDongyan Feng
3 shared publicationsCurtis A. Parvin
Division of Neuropathology, Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri (RES, KGG)
2 shared publicationsDenise A. Dorsey
Departments of Pathology and Immunology, Division of Neuropathology, Washington University School of Medicine, Saint Louis, Missouri
2 shared publicationsLisa L. Snipes
2 shared publications- Michael Brines
Laboratory of Biomedical Sciences, Institute for Bioelectronic Medicine, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY
2 shared publications
Latest Publications
- Open Access
- 1 December 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (23)
Macrophage depletion blocks congenital SARM1-dependent neuropathy
Axon loss contributes to many common neurodegenerative disorders. In healthy axons, the axon survival factor NMNAT2 inhibits SARM1, the central executioner of programmed axon degeneration. We identified 2 rare NMNAT2 missense variants in 2 brothers afflicted with a progressive neuropathy syndrome. The polymorphisms resulted in amino acid substitutions V98M and R232Q, which reduced NMNAT2 NAD+-synthetase activity. We generated a mouse model to mirror the human syndrome and found that Nmnat2V98M/R232Q compound-heterozygous CRISPR mice survived to adulthood but developed progressive motor dysfunction, peripheral axon loss, and macrophage infiltration. These disease phenotypes were all SARM1-dependent. Remarkably, macrophage depletion therapy blocked and reversed neuropathic phenotypes in Nmnat2V98M/R232Q mice, identifying a SARM1-dependent neuroimmune mechanism as a key driver of disease pathogenesis. These findings demonstrate that SARM1 induced inflammatory neuropathy and highlight the potential of immune therapy as a treatment for this rare syndrome and other neurodegenerative conditions associated with NMNAT2 loss and SARM1 activation.
- 1 December 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (23)
Open AccessMacrophage depletion blocks congenital SARM1-dependent neuropathy
Axon loss contributes to many common neurodegenerative disorders. In healthy axons, the axon survival factor NMNAT2 inhibits SARM1, the central executioner of programmed axon degeneration. We identified 2 rare NMNAT2 missense variants in 2 brothers afflicted with a progressive neuropathy syndrome. The polymorphisms resulted in amino acid substitutions V98M and R232Q, which reduced NMNAT2 NAD+-synthetase activity. We generated a mouse model to mirror the human syndrome and found that Nmnat2V98M/R232Q compound-heterozygous CRISPR mice survived to adulthood but developed progressive motor dysfunction, peripheral axon loss, and macrophage infiltration. These disease phenotypes were all SARM1-dependent. Remarkably, macrophage depletion therapy blocked and reversed neuropathic phenotypes in Nmnat2V98M/R232Q mice, identifying a SARM1-dependent neuroimmune mechanism as a key driver of disease pathogenesis. These findings demonstrate that SARM1 induced inflammatory neuropathy and highlight the potential of immune therapy as a treatment for this rare syndrome and other neurodegenerative conditions associated with NMNAT2 loss and SARM1 activation.
- 6 June 2019
- Published by Elsevier
- Vol. 145, 1-12
Mitochondriopathy: The unifying concept in distal neuropathies?
- 6 June 2019
- Published by Elsevier
- Vol. 145, 1-12
Mitochondriopathy: The unifying concept in distal neuropathies?
- Open Access
- 7 April 2017
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 14 (1) , 1-10
Diffusion MRI quantifies early axonal loss in the presence of nerve swelling
Magnetic resonance imaging markers have been widely used to detect and quantify white matter pathologies in multiple sclerosis. We have recently developed a diffusion basis spectrum imaging (DBSI) to distinguish and quantify co-existing axonal injury, demyelination, and inflammation in multiple sclerosis patients and animal models. It could serve as a longitudinal marker for axonal loss, a primary cause of permanent neurological impairments and disease progression. Eight 10-week-old female C57BL/6 mice underwent optic nerve DBSI, followed by a week-long recuperation prior to active immunization for experimental autoimmune encephalomyelitis (EAE). Visual acuity of all mice was assessed daily. Longitudinal DBSI was performed in mouse optic nerves at baseline (naïve, before immunization), before, during, and after the onset of optic neuritis. Tissues were perfusion fixed after final in vivo scans. The correlation between DBSI detected pathologies and corresponding immunohistochemistry markers was quantitatively assessed. In this cohort of EAE mice, monocular vision impairment occurred in all animals. In vivo DBSI detected, differentiated, and quantified optic nerve inflammation, demyelination, and axonal injury/loss, correlating nerve pathologies with visual acuity at different time points of acute optic neuritis. DBSI quantified, in the presence of optic nerve swelling, ~15% axonal loss at the onset of optic neuritis in EAE mice. Our findings support the notion that axonal loss could occur early in EAE mice. DBSI detected pathologies in the posterior visual pathway unreachable by optical coherence tomography and without confounding inflammation induced optic nerve swelling. DBSI could thus decipher the interrelationship among various pathological components and the role each plays in disease progression. Quantification of the rate of axonal loss could potentially serve as the biomarker to predict treatment outcome and to determine when progressive disease starts.
- 7 April 2017
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 14 (1) , 1-10
Open AccessDiffusion MRI quantifies early axonal loss in the presence of nerve swelling
Magnetic resonance imaging markers have been widely used to detect and quantify white matter pathologies in multiple sclerosis. We have recently developed a diffusion basis spectrum imaging (DBSI) to distinguish and quantify co-existing axonal injury, demyelination, and inflammation in multiple sclerosis patients and animal models. It could serve as a longitudinal marker for axonal loss, a primary cause of permanent neurological impairments and disease progression. Eight 10-week-old female C57BL/6 mice underwent optic nerve DBSI, followed by a week-long recuperation prior to active immunization for experimental autoimmune encephalomyelitis (EAE). Visual acuity of all mice was assessed daily. Longitudinal DBSI was performed in mouse optic nerves at baseline (naïve, before immunization), before, during, and after the onset of optic neuritis. Tissues were perfusion fixed after final in vivo scans. The correlation between DBSI detected pathologies and corresponding immunohistochemistry markers was quantitatively assessed. In this cohort of EAE mice, monocular vision impairment occurred in all animals. In vivo DBSI detected, differentiated, and quantified optic nerve inflammation, demyelination, and axonal injury/loss, correlating nerve pathologies with visual acuity at different time points of acute optic neuritis. DBSI quantified, in the presence of optic nerve swelling, ~15% axonal loss at the onset of optic neuritis in EAE mice. Our findings support the notion that axonal loss could occur early in EAE mice. DBSI detected pathologies in the posterior visual pathway unreachable by optical coherence tomography and without confounding inflammation induced optic nerve swelling. DBSI could thus decipher the interrelationship among various pathological components and the role each plays in disease progression. Quantification of the rate of axonal loss could potentially serve as the biomarker to predict treatment outcome and to determine when progressive disease starts.
- 1 January 2014
- Published by Elsevier in Handbook of Clinical Neurology
- Vol. 126, 579-602
Autonomic neuropathy in experimental models of diabetes mellitus
- 1 January 2014
- Published by Elsevier in Handbook of Clinical Neurology
- Vol. 126, 579-602
Autonomic neuropathy in experimental models of diabetes mellitus
- 1 December 2011
- Published by Elsevier in Experimental Neurology
- Vol. 232 (2) , 126-135
Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2Akita) diabetic mouse sympathetic ganglia
- 1 December 2011
- Published by Elsevier in Experimental Neurology
- Vol. 232 (2) , 126-135
Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2Akita) diabetic mouse sympathetic ganglia
- 1 March 2009
- Published by Elsevier in Experimental Neurology
- Vol. 216 (1) , 207-218
Neuritic dystrophy and neuronopathy in Akita (Ins2) diabetic mouse sympathetic ganglia
- 1 March 2009
- Published by Elsevier in Experimental Neurology
- Vol. 216 (1) , 207-218
Neuritic dystrophy and neuronopathy in Akita (Ins2) diabetic mouse sympathetic ganglia
- Open Access
- 1 December 2008
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
- Vol. 67 (12) , 1166-1186
Synaptic Ultrastructural Alterations Anticipate the Development of Neuroaxonal Dystrophy in Sympathetic Ganglia of Aged and Diabetic Mice
Neuroaxonal dystrophy, a distinctive axonopathy characterized by marked enlargement of distal axons, is the hallmark pathologic alteration in aged and
- 1 December 2008
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
- Vol. 67 (12) , 1166-1186
Open AccessSynaptic Ultrastructural Alterations Anticipate the Development of Neuroaxonal Dystrophy in Sympathetic Ganglia of Aged and Diabetic Mice
Neuroaxonal dystrophy, a distinctive axonopathy characterized by marked enlargement of distal axons, is the hallmark pathologic alteration in aged and
- 1 January 2008
- Published by Elsevier in Experimental Neurology
- Vol. 209 (1) , 161-170
Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice
- 1 January 2008
- Published by Elsevier in Experimental Neurology
- Vol. 209 (1) , 161-170
Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice
- 23 July 1993
- Published by Elsevier in Brain Research
- Vol. 617 (2) , 343-348
Characterization of NADPH diaphorase activity in rat sympathetic autonomic ganglia—effect of diabetes and aging
- 23 July 1993
- Published by Elsevier in Brain Research
- Vol. 617 (2) , 343-348
Characterization of NADPH diaphorase activity in rat sympathetic autonomic ganglia—effect of diabetes and aging